Stockreport

Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF weeks) across all four genetic cohorts, and management said it will not seek regulatory filings or run additional setmelanotide trials in these indications. Post-hoc a [Read more]